TRDA VS AORT Stock Comparison

PerformanceTechnicalsEarningsProfitVolatility
PerformanceTechnicalsEarningsProfitVolatility

Performance

TRDA
10/100

TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

AORT
51/100

AORT returned 13.17% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 50 of 100.

Technicals

TRDA
71/100

TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

AORT
50/100

AORT receives a 50 of 100 based on 14 indicators. 6 are bullish, 6 are bearish.

Earnings

TRDA
10/100

TRDA has missed earnings 4 times in the last 20 quarters.

AORT
29/100

AORT has missed earnings 4 times in the last 20 quarters.

Profit

TRDA
10/100

Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.

AORT
16/100

Out of the last 20 quarters, AORT has had 3 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

TRDA
51/100

TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.

AORT
47/100

AORT has had a lower than average amount of volatility over the last 12 months giving it a score of 47 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Entrada Therapeutics, Inc. Common Stock Summary

Nasdaq / TRDA
Healthcare
Biotechnology
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Artivion, Inc. Summary

New York Stock Exchange / AORT
Healthcare
Medical - Devices
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.